# Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

> **NCT06859008** · PHASE1 · RECRUITING · sponsor: **City of Hope Medical Center** · enrollment: 37 (estimated)

## Conditions studied

- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Recurrent Diffuse Large B-Cell Lymphoma
- Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
- Recurrent Grade 1 Follicular Lymphoma
- Recurrent Grade 2 Follicular Lymphoma
- Recurrent Grade 3a Follicular Lymphoma
- Recurrent Mantle Cell Lymphoma
- Recurrent Nodal Marginal Zone Lymphoma
- Recurrent Splenic Marginal Zone Lymphoma
- Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Refractory Diffuse Large B-Cell Lymphoma
- Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
- Refractory Grade 1 Follicular Lymphoma
- Refractory Grade 2 Follicular Lymphoma
- Refractory Grade 3a Follicular Lymphoma
- Refractory Mantle Cell Lymphoma
- Refractory Nodal Marginal Zone Lymphoma
- Refractory Splenic Marginal Zone Lymphoma

## Interventions

- **PROCEDURE:** Biopsy
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Bone Marrow Aspiration
- **PROCEDURE:** Bone Marrow Biopsy
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Magnetic Resonance Imaging
- **OTHER:** Questionnaire Administration
- **DRUG:** Sonrotoclax
- **DRUG:** Zanubrutinib

## Key facts

- **NCT ID:** NCT06859008
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-25
- **Primary completion:** 2029-01-31
- **Final completion:** 2029-01-31
- **Target enrollment:** 37 (ESTIMATED)
- **Last updated:** 2026-04-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06859008

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06859008, "Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06859008. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*